205923-56-4

URI: https://gptkb.org/entity/205923-56-4
GPTKB entity
Statements (32)
Predicate Object
gptkbp:instanceOf gptkb:chemical_compound
gptkbp:administeredBy oral
gptkbp:ATCCode N05CM25
gptkbp:CASNumber gptkb:205923-56-4
gptkbp:developedBy gptkb:Merck_&_Co.
gptkbp:eliminationHalfLife 12 hours
gptkbp:excretion urine
feces
gptkbp:hasMolecularFormula C23H23ClN6O2
gptkbp:hasTherapeuticUse treatment of insomnia
gptkbp:hasUNII 7X9Q64V895
https://www.w3.org/2000/01/rdf-schema#label 205923-56-4
gptkbp:isApprovedDrug true
gptkbp:IUPACName [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone
gptkbp:legalStatus prescription only
gptkbp:marketedAs gptkb:Belsomra
gptkbp:mechanismOfAction orexin receptor antagonist
gptkbp:metabolism liver
gptkbp:molecularWeight 450.92 g/mol
gptkbp:name gptkb:Suvorexant
gptkbp:pregnancyCategory C (US)
gptkbp:proteinBinding 99%
gptkbp:PubChem_CID CHEMBL2108507
24964624
DB09025
gptkbp:routeOfAdministration oral
gptkbp:sideEffect dizziness
headache
somnolence
abnormal dreams
gptkbp:bfsParent gptkb:Erbitux
gptkbp:bfsLayer 6